Sleuth Studio
Customer Stories

How one of the largest diagnostics companies reaches drug developers before they pick a partner

Sleuth shows companies that sell to pharma which drug developers to reach, and when, from a live view of the market. One of the world’s largest oncology diagnostics companies used Studio to map every program in four newer kinds of cancer drug, see which patients the late-stage trials will add, and find the sponsors whose partner decisions are coming up.

A global oncology diagnostics company

How one of the largest diagnostics companies reaches drug developers before they pick a partner

Download the full case study

Partner

One of the world’s largest oncology diagnostics companies. Its biopharma team sells tests to drug developers and runs those partnerships.

Challenge

Its roadmap and sales plan are set well ahead, but each new drug type or late-stage readout changes who needs testing. Market reports were out of date on arrival and never said which sponsors to call.

Approach

In Studio, the team mapped every program and sponsor in four drug types, tied late-stage trials to the patients they’d add, and followed the drugs into autoimmune disease. Monitoring keeps it current.

Outcome

The team decides which tests to build and which sponsors to call from one current view, and reaches each sponsor before it chooses a diagnostic partner.

Where each drug type is headed, projected from current positions

A projection of approved cancer drugs by type from today to 2030, with radiopharmaceuticals lit.
Approved cancer drugs by type, from today to 2030.

What the market will need in three years

Each late-stage trial that succeeds changes who gets treated and which diagnostics they need, and most of what’s still open comes after treatment starts. Studio tied every late-stage program in four drug types to the patients that enroll in it, so the team could plan which tests to have ready.

Today’s late-stage trials show what each drug type will need next

Late-stage programs in four drug types, one square each, with the testing need each adds: response tracking for ADCs, leftover-disease checks for bispecifics, disagreeing markers for radiopharmaceuticals, and tracking after infusion for cell therapies.
Programs in Phase 3 or filed, most reading out in the next few years. One square each.

See where the drug types you sell into go next

Cell therapies and T-cell engagers are moving into autoimmune disease, so the team can plan tests there early:

  • A large pharma bought a cell therapy maker to work across cancer and autoimmune disease.
  • A cancer cell therapy program moved into autoimmune disease.
  • A two-target CAR-T was cleared to start lupus trials.
  • A T-cell engager developer is starting several Phase 2 studies in autoimmune disease.

Which sponsors to reach first, and when

Every drug developer picks its partners at set moments, and it usually chooses a diagnostic partner while it designs the pivotal trial. Studio placed every sponsor’s programs on that timeline, so the team can reach them first.

A timeline of six anonymized sponsors and the window when each is likely to choose a diagnostic partner.
When each sponsor is likely to choose a diagnostic partner. An excerpt.

Open each pitch on that sponsor’s own programs

Studio alerts on sponsors’ programs, beside one pitch sentence with two endings written for two sponsors.
From a monitored Studio workspace, sponsors anonymized.

Now the team calls each sponsor before it picks a diagnostic partner, and opens on that sponsor’s own programs.

Download
Use case

See which pharma in your market are about to choose a partner

Bring your own asset, target, or indication, and Sleuth builds the analysis for you.

More from Sleuth